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113Results of the endovascular abdominal aortic
aneurysm repair using the Anaconda aortic
endograft
Antonio Freyrie, MD, Enrico Gallitto, MD, Mauro Gargiulo, MD, Gianluca Faggioli, MD,
Claudio Bianchini Massoni, MD, Chiara Mascoli, MD, Rodolfo Pini, MD, and Andrea Stella, MD,
Bologna, Italy
Objective: The objective of this study was to evaluate early and late results of the Anaconda aortic endograft (Vascutek,
Terumo, Inchinnan, Scotland) in a single-center experience.
Methods: From September 2005 to March 2012, patients underwent endovascular aortic repair for abdominal aortic
aneurysm (AAA) with Anaconda endograft were prospectively enrolled in a dedicated database. Demographic and aor-
toiliac morphological data were considered. Preoperative planning was based on thoracoabdominal and pelvic computed
tomography angiography. Follow-up included duplex ultrasound or computed tomography angiography at 1, 6, and
12 months and yearly thereafter. Primary end points were technical success, early and late primary and primary assisted
clinical success (CS), overall and AAA-related survival and freedom from reinterventions. Secondary end points were
endoleaks (ELs), steno-obstructive iliac leg complications, and AAA shrinkage.
Results: An Anaconda endograft was implanted in 177 patients (male 94%; mean age, 73.3 6 7.4 years; American Society
of Anesthesiologists class III-IV, 85% and 9%, respectively). The mean AAA diameter, neck length, and diameter were
55 6 9.7 mm, 26.7 6 10 mm, and 23 6 2.3 mm, respectively. There was an aortic neck angle >60 in 44 (25%) patients.
Iliac angles >90 were observed in 152 (43%) iliac axes. Technical success was 98.9%. Early CS was 96%. Mean follow-up
was 33 6 23.3 months. Late assisted CS was 97.7%. Survival at 12, 24, and 36 months was 96.4%, 89%, and 86.2%,
respectively. There was only one case of late AAA-related mortality. Freedom from reintervention was 94%, 92%, and 85%
at 12, 24, and 36 months, respectively. Three (1.7%) conversions occurred during follow-up. There were 14.1% ELs at the
completion angiography (EL Ia, 1.1%; EL II, 13%). Late ELs were 20.2% (EL Ia, 1.1%; EL Ib, 2.2%; EL II, 16.9%). Iliac
leg complications occurred in 5.6% of the cases. An AAA shrinkage >5 mm was observed in 130 (73.4%) patients. In 7
(4%) cases there was an AAA enlargement >5 mm.
Conclusions: Data in our series demonstrate that the Anaconda endograft has good early and late results in the treatment
of AAAs. (J Vasc Surg 2014;60:1132-9.)Since its introduction, the endovascular treatment
(endovascular aortic repair [EVAR]) of abdominal aortic
aneurysms (AAAs) has been widely accepted1 and become
the preferred treatment option in several centers. The pub-
lished randomized trials, comparing EVAR and open repair
(OR), showed advantages of EVAR in terms of 30-day out-
comes with no difference in mid- and long-term results.2-5
These trials refer to ﬁrst-generation endografts and only
few long-term results on more recent endografts are avail-
able.6,7 Technical solutions and new devices were required
to overcome the major EVAR problems and improve the
long-term outcomes. The Anaconda endograft (Vascutek,
Terumo, Inchinnan, Scotland) is a relatively new-
generation device with a unique concept of proximal seal-
ing, repositionability of the main body, and adaptabilityVascular Surgery, University of Bologna.
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2of the iliac legs. The aim of the study was to report early
and late EVAR results using the Anaconda aortic endograft
in a single-center experience. To our knowledge, this is the
largest single-center Anaconda experience, with the longest
follow-up reported in literature. The study was conducted
without funding by the company that produced the device.
METHODS
Patient selection. Data from patients who underwent
EVAR with the Anaconda endograft between September
2005 to March 2012 were prospectively collected in a
dedicated database. Cardiovascular risk factors, comorbid-
ities, and anatomical aortic-iliac features were preopera-
tively recorded. Intraoperative details and follow-up data
were evaluated.
The Anaconda endograft was used, according to the
speciﬁc device instructions for use, in AAAs with proximal
neck length $15 mm and diameter between 16 and
31 mm. The distal landing zone length was $15 mm
and the diameter was between 7 and 17 mm. Asymptom-
atic AAAs with diameter $50 mm, symptomatic AAAs
(abdominal back pain, contained rupture, and distal embo-
lizations), and infrarenal aortic dilatation (>35 mm) associ-
ated with iliac aneurysms of diameter $30 mm were
enrolled. Patients with acute AAA rupture, proximal neck
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>90 were excluded. Inadequate arterial access to intro-
duce a delivery system of 20 French to 22 French for the
main body and 18 French for the contralateral iliac leg
were also exclusion criteria. Tortuous iliac access was not
considered as a contraindication.
Because of the study type and the endograft character-
istics (marketed under European Conformity license, April
2005), the Ethical Committee of our hospital did not ﬁnd
it necessary to approve the project. All patients provided
their written consent.
Preoperative planning. Patients were preoperatively
studied using a thoracoabdominal and pelvic computed to-
mography angiography (CTA) with slices <5 mm of thick-
ness. Images from 2 cm above the celiac axis to the femoral
artery bifurcation were evaluated. Preoperative CTA was
performed by radiologists with experience in vascular pa-
thology and were evaluated by three vascular surgeons
(A.F., M.G., A.S.) with EVAR experience (>10 years).
Since 2009, the preoperative evaluations were performed
using a dedicated software for analysis of the vessels
(3Mensio; Vascular Imaging Software, Bilthoeven,
Netherlands). The characteristics of the proximal aortic
neck (diameter, length, angles, presence of calciﬁcation or
thrombus), iliac arteries (diameter, tortuosity, presence of
calciﬁcation or wall thrombus) and femoral access were
analyzed. The endografts were planned by vascular sur-
geons with experience in EVAR.
Endograft and implant technique. We described the
Anaconda endograft characteristics and the details of the
implant in our previous reports.8,9 Since October 2011,
the new Anaconda One-Lok device is commercially avail-
able. Two nitinol rings were added in the main body and
the iliac gate diameter was standardized to 10.5 mm (the
iliac leg device always has a proximal diameter of 12 mm).
If we observed an iliac leg stenosis $50% at completion
of multiplanar angiography, a percutaneous balloon angio-
plasty (PTA) and/or stenting was performed. In cases of
narrow aortic bifurcation (#20 mm) an iliac kissing stent
was used.
End points and deﬁnitions. Primary end points were:
technical success (TS), early and late clinical success (CS)
(according to the EVAR Reporting Standards published
by Chaikof et al10), overall and AAA-related survival (S)
and freedom from reinterventions (FFRs).
Secondary end points were endoleaks (ELs), steno-
obstructive iliac leg complications (ILCs), and AAA
shrinkage.
TS was deﬁned as successful access to the arterial sys-
tem, successful deployment of the endograft with secure
proximal and distal sealing, and ﬁxation of the attachment
devices, demonstrating safe and effective exclusion of the
AAAs without type I or III ELs and patent endograft
without signiﬁcant twists, kinks, or obstruction using intra-
operative angiography measurement in the ﬁrst 24 hours.10
CS was deﬁned as successful deployment of the endo-
vascular device at the intended location without death as
a result of aneurysm-related treatment, types I and IIIELs, graft infection, or thrombosis, aneurysm expansion
(diameter >5 mm, or volume >5%), aneurysm rupture,
or conversion to OR.10 In cases with type II EL, CS was
only claimed in the absence of aneurysm expansion. Pri-
mary CS was deﬁned as CS without the need for an addi-
tional or secondary surgical or endovascular procedure.
Secondary CS was deﬁned as CS obtained with the use of
an additional or secondary surgical procedure. Clinical fail-
ure included a failure to deploy the endovascular device at
the intended location, the presence of a type I or III EL,
graft thrombosis or infection, graft dilatation of $20% in
diameter, graft migration, failure of device integrity, aneu-
rysm expansion or rupture, conversion to OR, or death. CS
is reported as short-term CS (30 days) and midterm CS
(3 years of follow-up).10
ELs were classiﬁed according to the White-May deﬁni-
tions.11 Postimplant syndrome was deﬁned as postopera-
tive fever >38C during more than 72 hours and it was
not considered as a major complication. AAA shrinkage
was deﬁned as an AAA diameter reduction $5 mm.
Endograft migration was deﬁned as the craniocaudal dislo-
cation of the endograft >5 mm.
Statistical analysis. Continuous variables are reported
as mean, range, and standard deviation. Categorical data are
given as frequencies. S, FFR, and ILCs were estimated using
the Kaplan-Meyer method. Differences between means
were evaluated using the Student t-test and Fisher exact test.
Signiﬁcance was assumed at a P value # .05. The statistical
evaluations were performed using SPSS for Windows
(version 15.0; SPSS Inc, Chicago, Ill). The statistical eval-
uation was performed by 2 vascular surgeons (C.B.M., R.P.)
with experience in statistical analysis and SPSS software.
Follow-up. According to our institution follow-up
protocol for EVAR, all patients underwent Doppler ultra-
sound (US) at discharge, CTA at 1 month, US at
6 months, CTA at 12 months and US yearly thereafter.
When a type II EL with sac enlargement was detected, we
usually performed contrast-enhanced US (CEUS). In case
of any diagnostic suspicions or reinterventions, we always
performed a CTA. Anteroposterior and laterolateral AAA
diameters were measured. The presence of EL, endograft
migration, or ILC were evaluated. In cases of diagnostic
doubts we consider CEUS together with CTA as the gold
standard to deﬁne the origin of the EL and the post-
processing CTA reconstruction using software dedicated
for visceral vessel analysis as the gold standard regarding
the AAA sac sizing.
Postoperative CTAs were performed by radiologists
with experience in vascular pathology and were evaluated
by 3 vascular surgeons (A.F., M.G., A.S.) with EVAR expe-
rience (>10 years). US and CEUS were performed and
evaluated by 2 vascular surgeons with EVAR and US expe-
rience (E.G., C.M.).
RESULTS
Patients. From September 2005 to March 2012, 692
AAAs were treated electively at the Vascular Surgery of
Bologna University. Four hundred sixty-three patients
Table I. Cardiovascular risk factors and clinical
comorbidities of patients
No. %
Cardiovascular risk factor
Hypertension 149 84
Smoking 39 17
Dyslipidemia 74 42
Diabetes 19 11
BMI $ 30 46 26
Comorbidities
CAD 48 27
AF 18 10
COPD 74 42
CRD (creatinine >1.3 mg/dL) 57 32
PAOD 3 2
OAT 23 13
AF, Atrial ﬁbrillation; BMI, body mass index; CAD, coronary artery disease;
COPD, chronic obstructive pulmonary disease; CRD, chronic renal disease;
OAT, oral anticoagulant therapy; PAOD, peripheral artery occlusive disease.
Table II. Preoperative anatomic features of the aortic-
iliac axis evaluated using computed tomography
angiography (CTA)
Infrarenal neck characteristic Mean, mm SD, mm
Proximal length 26.7 610
Proximal diameter 23.1 62
No. %
Angle $60 44 25
Calciﬁcations $50 32 18
Thrombosis $50 39 22
Iliac characteristic Mean, mm SD, mm
Right iliac diameter 15.9 610
Left iliac diameter 15.9 610
No. %
Right iliac $90 64 36
Left iliac $90 88 49
SD, Standard deviation.
Table III. Intra- and perioperative data
Procedure No. %
Main body repositioning 75 42
Main body ballooning 24 13.6
Docking zone ballooning 102 57.6
Iliac leg ballooning 248 70
Iliac leg stenting 15 8.5
Mean SD
Contrast medium 125.2 649.5
Contralateral gate cannulation time, minutes 2.3 61.4
Procedure time, minutes 154.5 636.6
Fluoroscopy time, minutes 19.9 66.5
Hospitalization, days 6 64
Anesthesia No. %
General 29 16.4
Locoregional 147 83
Local 1 0.6
SD, Standard deviation.
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treated using the Anaconda aortic endograft. In the
remaining cases (62%), we used a Cook Zenith endograft
(CookMedical Inc, Bloomington, Ind),Medtronic Talent/
Endurant endograft (MedtronicCardiovascular, SantaRosa,
Calif), or Gore Excluder endograft (W. L. Gore & Associ-
ates, Flagstaff, Ariz), according to the aortic-iliac anatomy.
Regarding the Anaconda series, the mean age was
73.3 6 7.4 years (range, 47-89 years), 167 (94.4%) were
male and 10 (5.6%) female. The mean preoperative creati-
nine value was 1.2 6 0.8 mg/dL (range, 0.7-9.7 mg/dL).
The American Society of Anesthesiologists risk score was
III and IV in 151 (85.3%) and 16 (9%) cases, respectively.
Comorbidities and cardiovascular risk factors are described
in Table I. The mean AAA diameter was 55 6 9.7 mm
(range, 45-99 mm). Anatomical aortoiliac features are
summarized in Table II. In two patients (1.3%) there was
an asymptomatic contained aortic rupture detected on
the preoperative CTA (treated expeditiously but not in
emergency) and two AAAs (1.3%) had inﬂammatory fea-
tures at the preoperative CTA. One patient had a horse-
shoe kidney. The inferior mesenteric artery was patent in
63.3% preoperatively.
Procedure and early results (30 days). The mean
main body oversize was 16 6 0.8% (range, 5%-33%) and
the main body was repositioned in 75 cases (42%). The
mean time of controlateral gate cannulation was 2.3 6
1.4 minutes. Fifteen (8.5%) adjunctive PTA stentings of
the iliac leg endograft were performed (we used bare
stents: 10 balloon-expandable and ﬁve self-expandable).
In three (1.7%) cases, a kissing stent technique was used
at the aortic bifurcation level because the diameter
was <20 mm. In 23 (12.9%) patients there was an inten-
tional hypogastric artery coverage and when it was bilateral
(3 cases; 1.7%) a unilateral surgical external to internal iliac
bypass was performed. Intra- and perioperative details are
reported in Table III.
TS was 98.9%. No intraoperative mortality, abortive
procedure, or OR conversions occurred. At the completionangiography there were two (1.1%) type Ia ELs. No
endograft limb occlusions or type III ELs were detected
at the end of the procedure.
Early CS was achieved in 170 cases (96%). There was
one case (0.5%) of postoperative paraplegia9 in a patient
with bilateral hypogastric artery coverage. Two patients
(1.1%) had an iliac leg obstruction and two patients
(1.1%) died within 30 days. One patient died on the second
postoperative day due to a massive myocardial infarction.
The other died on the 13th postoperative day due to multi-
organ failure after a venous intestinal infarction. Both deaths
were not AAA-related. The mean postoperative creatinine
Fig 1. Long-term survival (S) of patients according to the Kaplan-Meyer method.
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There were no statistical differences between the mean
pre- and postoperative creatinine levels. Postimplantation
syndrome occurred in 41 cases (23.2%).
Survival, complications, and secondary procedure.
Eleven patients (6%) were lost to follow-up. The mean
follow-up was 32.9 6 23.3 months (range, 1-77 months).
S at 12, 24, and 36 months were 96.4%, 89.1%, and 86.2%,
respectively (Fig 1). There was one case of late AAA-related
death (0.5%).12 There were two (1.1%) asymptomatic renal
artery occlusions detected using CTA at the 12-month
follow-up. Both patients did not report any symptoms
during this period and they had no renal function wors-
ening. Primary and assisted late CS was 87% and 97.7%,
respectively. FFR at 12, 24, and 36 months were 93.6%,
92%, and 85% (Fig 2). No endograft migrations were
detected during follow-up. Reinterventions are summa-
rized in Table IV. There were three (1.7%) conversions:
two due to an asymptomatic AAA-contained rupture in
patients with persistent type II ELs and one because of an
endograft thrombosis. All patients who underwent con-
version to OR are currently alive with no complications.
ELs. At the completion procedure angiography, there
were 25 (14.1%) ELs: two (1.1%) type Ia and 23 (13%) type
II. The ﬁrst type Ia EL occurred in an AAA with a neck length
and diameter of 25 and 30 mm, respectively. The main body
size used was 34 mm. A chimney technique was used to seal
the EL and solve the AAA enlargement at 6 months of
follow-up. In the second case, the neck length and diameterwere 20 and 24 mm, respectively, and the main body size used
was 28 mm. At 3 months of follow-up, the EL completely
sealed and at 1 year the AAA shrinkage was >2 cm. No distal
type I or III ELs occurred at the end of the procedure.
During the follow-up, the late EL rate was 20.2%.
There were 1.1% of type Ia EL, 2.2% of type Ib EL, and
16.9% of persistent type II EL. The ﬁrst proximal type I
EL was detected in an 88-year-old woman who developed
a type II thoracoabdominal aneurysm at 36 months of
follow-up. Because of her severe clinical condition, a surgical
treatment was not suitable. The second proximal type I EL
occurred in a 15-mmneck length with a proximal neck angle
>60. This patient died from heart failure before the EL
could be treated. All the distal type I ELs were successfully
treated with an iliac leg extension. No late type III or IV
ELs were detected. No late endograft migrations occurred.
Steno-obstructive iliac complications and AAA
shrinkage. Iliac leg steno-obstructive complications oc-
curred in 10 patients (5.6%of the cases). They are reported in
Table IV. There were eight of 354 (2.2%) iliac leg throm-
bosis, one iliac leg stenosis, and one external iliac artery
thrombosis. All of these patients were symptomatic (clau-
dication, 8/10; acute limb ischemia, 1 of 10) except one.
Only in one case, the endograft limb landed in the external
iliac artery. Freedom from total iliac complication was 93%,
92%, and 88% at 12, 24, and 36months, respectively (Fig 3).
The mean and median AAA shrinkage was 10 6
8.7 mm (range, 10 to 44). The AAA shrinkage was
observed in 130 (73.4%) patients. In 40 (22.6%) cases,
Fig 2. Freedom from reinterventions (FFRs) of patients according to the Kaplan-Meyer method.
Table IV. Cause, type of reintervention, and time of occurrence during follow-up
No. Reintervention Technique Cause Follow-up, months
1 PTA stenting iliac leg Endovascular Main body/iliac leg thrombosis 4
2 Conversion OR Iliac leg thrombosis 9
3 Renal artery chimney Endovascular EL Ia 6
4 PTA iliac leg and stenting of external iliac artery Endovascular Iliac leg stenosis 4
5 Urokinasi and PTA stenting iliac leg Endovascular Iliac leg thrombosis 31
6 Iliac leg surgical repair OR EL Ib 33
7 Iliac leg extension Endovascular EL Ib 7
8 IMA clipping OR EL II and AAA sac enlargement 22
9 Iliac leg extension Endovascular EL Ib 45
10 PTA stenting external iliac artery Endovascular External iliac thrombosis 6
11 Urokinasi and PTA iliac leg artery Endovascular Iliac leg thrombosis 4
12 PTA stenting external iliac artery Endovascular Iliac leg thrombosis 0
13 Iliac leg extension Endovascular EL Ib 35
14 Urokinasi and PTA stenting iliac leg Endovascular Iliac leg thrombosis 4
15 Conversion OR Contained aortic rupture 36
16 Conversion OR Contained aortic rupture 32
17 PTA iliac leg and stenting external iliac artery Endovascular Iliac leg thrombosis 0
18 IMA clipping OR EL II and AAA sac enlargement 35
19 Urokinasi and PTA stenting iliac leg Endovascular Iliac leg thrombosis 23
20 Surgical drainage OR Retroperitoneal hematoma 0
AAA, Abdominal aortic aneurysm; EL, endoleak; IMA, inferior mesenteric artery; OR, open repair; PTA, percutaneous balloon angioplasty.
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AAA enlargement >5 mm (2 type Ia ELs, 1 type Ib EL,
and 4 type II ELs).
DISCUSSION
Since the early EVAR experience, several devices have
been proposed but no single device seems to completely
solve all the problems associated with endovascular AAAmanagement. Published data, with long-term follow-up,
reported results of the ﬁrst-generation endografts but it is
possible that they could have underestimated the real effec-
tiveness and durability of EVAR. The Anaconda is a rela-
tively new-generation endograft, with a speciﬁc proximal
sealing and iliac adaptability, that showed promising early
and midterm results. Our previous articles report on the
excellent results of the Anaconda at early and midterm
Fig 3. Freedom from total iliac complications of patients according to the Kaplan-Meyer method.
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iac anatomy.13
In the present report we describe, to our knowledge,
the largest single-center clinical experience using the
Anaconda endograft reported in the published literature,
with a mean follow-up of 32.9 months; TS was 98.9%.
This is comparable with our previous reports, of single
and multicenter experience.14-16 In a previous article we re-
ported the preliminary results of the Italian Anaconda
multicenter registry.17 The high early technical and CS
are similar with our data. The 30-day mortality rates of
1.1% in our series compares positively with the 1.8% re-
ported in the EndoVascular Aneurysm Repair 1 (EVAR1)
trial.3 The low early and late type Ia EL rate (1.1%) is
comparable with the Zenith and Excluder published
trials.6,18,19 The absence of migration suggests a good
endograft sealing and anchoring force, previously demon-
strated in vitro.20 In our opinion, the neck morphology
evaluation is very important to have excellent results. Ac-
cording to the instructions for use, we implanted the
Anaconda endograft exclusively in cases with a proximal
neck length $15 mm. Severe angulations,21 calciﬁcations,
or thrombosis did not affect the outcomes.
One of the Anaconda’s peculiarities is the repositiona-
bilty of the main body. This feature allows an accurate
infrarenal placement even in angulated necks.21 In our
experience, the main body was repositioned in 42% of
the cases to achieve a more satisfactory endograft position.
Although there is a risk of renal embolization during therepositioning, this proved to be useful and effective in
terms of sealing and renal artery complications. Reposition-
ing rates reported in the literature varied between 67% and
10%.8,15-17,21 The nitinol saddle-shaped proximal ring
design facilitated adaptation to local anatomy, also during
the ﬁrst few days after implantation.14 When it occurs,
the valley of the proximal stent ring could migrate a few
millimeters upstream, occluding the renal artery ostium.
We reported two cases of late renal artery occlusion.
Some authors suggest that when the Anaconda is deployed
in the juxtarenal aorta, with the valleys functioning as scal-
lops around the renal oriﬁces, to place short balloon-
expandable stents in these oriﬁces to prevent renal artery
stenosis or occlusion.14 We prefer to deploy the top of
the Anaconda proximal ring stent below the renal artery
ostium to avoid the risk of renal artery occlusion due to
proximal saddle-shaped changes during follow-up. The
repositionability of the main body avoids the necessity to
use an aortic cuff in cases of nonsatisfactory deployment.
In our series, no proximal aortic cuffs were implanted dur-
ing the primary EVAR procedure, but some authors have
reported cases.8
We reported an overall rate of 5.6% for steno-
obstructive ILCs, with eight of 177 cases (4.5% of patients)
of iliac leg thrombosis. Considering a total of 354 iliac legs,
this percentage became 2.2% and this is within the range of
1.1% to 9%, reported in the literature for a variety of
endografts.2,6,22-25 Anatomic and endograft-related risk
factors are suggested. Severe iliac angulations, small
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eter are noted risk factors. The adaptability of the
Anaconda iliac legs leads us to treat very hostile iliac anat-
omy and it could explain the relatively high ILC rate re-
ported. Until December 2011, we implanted the
Anaconda endograft in combinations of small main body
diameter and corresponding iliac gate diameter with rela-
tively large diameter of iliac legs that could create an iliac
leg unfolding/compression. This mechanism could pro-
mote the iliac leg thrombosis. With the new One-Lok
design, this hypothetical limit is overcome. We previously
reported a relative reduction of ILC using an aggressive
PTA stenting approach of the iliac leg.9 According to our
previous experience, a three-projection completion angiog-
raphy is crucial to identify limb stenosis, for which adjunc-
tive stenting appears to ensure primary patency in midterm
follow-up.25
Because the main body requires 20.4-French to 22.5-
French outer diameter (6.8-7.5 mm) and the contralateral
limb requires 18.3-French outer diameter (6.1 mm), the
diameters of the Anaconda delivery system are relative large
compared with new-generation endografts with low-proﬁle
systems. It limits its use in cases in which the external iliac
artery diameter is <7/8 mm. In our opinion, the real
advantage of the Anaconda endograft is the adaptability
of the device in hostile and challenging anatomies in terms
of severe tortousities and angulations of the iliac arteries
and the proximal infrarenal neck.
The magnet-assisted system of contralateral gate can-
nulation could simplify and speed the procedure especially
in cases with challenging anatomy. The mean contralateral
gate cannulation time was 2.3 6 1.4 minutes and it com-
pares positively with the data reported by Saratzis et al
(4 minutes).15
Regarding the midterm results, our S (86.2% at
36 months), late primary and assisted CS (87% and 97.7%,
respectively at 36 months) and FFR (85% at 36 months)
data compared positively with data reported in the litera-
ture,26,27 and with randomized trials. A trial28 showed
82.46 3.7% of S at 3 years of follow-up in the EVAR group.
The long-term results of another trial29 reported 69% of
overall S and 70.4% of FFRs in the EVAR group.
A signiﬁcant AAA shrinkage was observed in 70.4% of
patients and in 22.6%, the AAA remained stable.CONCLUSIONS
In this clinical experience, the early and midterm out-
comes of the Anaconda endograft are satisfactory concern-
ing the treatment of AAAs with a minimum neck length of
15 mm. The Anaconda endograft was shown to be safe and
stable at the proximal attachment site (no migrations) and
proved, in the midterm, to effectively protect the patients
from aneurysm rupture. Because of the unique structural
characteristics, we suggest the use of the Anaconda endog-
raft also in cases with tortuous anatomy. Long-term and
multicenter studies are necessary to additionally verify the
reliability of this endograft.AUTHOR CONTRIBUTIONS
Conception and design: AF
Analysis and interpretation: AF, EG, MG, AS
Data collection: EG, CM
Writing the article: AF, EG
Critical revision of the article: MG, GF, AS
Final approval of the article: AF, AS
Statistical analysis: CBM, RP
Obtained funding: Not applicable
Overall responsibility: AF
REFERENCES
1. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft
implantation for abdominal aortic aneurysms. Ann Vasc Surg 1991;5:
491-9.
2. EVAR trial participants. Endovascular aneurysm repair versus open
repair in patients with abdominal aortic aneurysm (EVAR trial 1):
randomised controlled trial. Lancet 2005;365:2179-86.
3. United Kingdom EVAR Trial Investigators, Greenhalgh RM,
Brown LC, Powell JT, Thompson SG, Epstein D, et al. Endovascular
versus open repair of abdominal aortic aneurysm. N Engl J Med
2010;362:1863-71.
4. Brown LC, Powell JT, Thompson SG, Epstein DM, Sculpher MJ,
Greenhalgh RM. The UK EndoVascular Aneurysm Repair (EVAR)
trials: randomised trials of EVAR versus standard therapy. Health
Technol Assess 2012;16:1-218.
5. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT Jr,
Matsumura JS, Kohler TR, et al. Outcomes following endovascular vs
open repair of abdominal aortic aneurysm: a randomized trial. JAMA
2009;302:1535-42.
6. Pratesi C, Piffaretti G, Pratesi G, Castelli P; the ITalian Excluder
Registry Investigators. ITalian Excluder Registry and results of Gore
Excluder endograft for the treatment of elective infrarenal abdominal
aortic aneurysms. J Vasc Surg 2014;59:52-7.
7. Zandvoort HJ, Gonçalves FB, Verhagen HJ, Werson DA, Moll FL, de
Vries JP, et al. Results of endovascular repair of infrarenal aortic an-
eurysms using the Endurant stent graft. J Vasc Surg 2014;59:
1195-202.
8. Freyrie A, Gargiulo M, Rossi C, Losinno F, Testi G, Mauro R, et al.
Preliminary results of Anaconda aortic endografts: a single center study.
Eur J Vasc Endovasc Surg 2007;34:693-8.
9. Stella A, Freyrie A, Gargiulo M, Faggioli GL. The advantages of
Anaconda endograft for AAA. J Cardiovasc Surg (Torino) 2009;50:
145-52.
10. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg 2002;35:1048-60.
11. White GH, Yu W, May J, Chaufour X, Stephen MS. Endoleak as a
complication of endoluminal grafting of abdominal aortic aneurysms:
classiﬁcation, incidence, diagnosis, and management. J Endovasc Surg
1997;4:152-68.
12. Freyrie A, Testi G, Gargiulo M, Faggioli G, Mauro R, Stella A. Spinal
cord ischemia after endovascular treatment of infrarenal aortic aneu-
rysm. Case report and literature review. J Cardiovasc Surg (Torino)
2011;52:731-4.
13. Freyrie A, Testi G, Faggioli GL, Gargiulo M, Giovanetti F, Serra C,
et al. Ring-stents supported infrarenal aortic endograft ﬁts well in
abdominal aortic aneurysms with tortuous anatomy. J Cardiovasc Surg
(Torino) 2010;51:467-74.
14. Rödel SG, Geelkerken RH, Prescott RJ, Florek HJ, Kasprzak P,
Brunkwall J. The Anaconda AAA stent graft system: 2-year clinical and
technical results of a multicentre clinical evaluation. Eur J Vasc
Endovasc Surg 2009;38:732-40.
15. Saratzis N, Melas N, Saratzis A, Lazarides J, Ktenidis K, Tsakiliotis S,
et al. Anaconda aortic stent-graft: single-center experience of a new
commercially available device for abdominal aortic aneurysms.
J Endovasc Ther 2008;15:33-41.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 5 Freyrie et al 113916. Majumder B, Urquhart G, Edwards R, Irshad K, Velu R, Reid DB.
Early clinical experience with the Anaconda re-deployable endograft in
106 patients with abdominal aortic aneurism: the west of Scotland
Anaconda registry. Scott Med J 2012;57:61-5.
17. Freyrie A, Gargiulo M, Fargion A, Gallitto E, Pratesi C, Stella A.
Anaconda(TM) Italian Registry Participating Physicians Anaconda: the
Italian Registry. Study protocol and preliminary perioperative results.
J Cardiovasc Surg (Torino) 2011;52:629-35.
18. Greenberg RK, Chuter TA, Cambria RP, Sternbergh WC 3rd,
Fearnot NE. Zenith abdominal aortic aneurysm endovascular graft.
Vasc Surg 2008;48:1-9.
19. Peterson BG, Matsumura JS, Brewster DC, Makaroun MS. Five year
report of a multicenter controlled clinical trial of open versus endo-
vascular treatment of abdominal aortic aneurysms. J Vasc Surg
2007;45:885-90.
20. Bosman WM, Steenhoven TJ, Suárez DR, Hinnen JW, Valstar ER,
Hamming JF. The proximal ﬁxation strength of modern EVAR grafts
in a short aneurysm neck. An in vitro study. Eur J Vasc Endovasc Surg
2010;39:187-92.
21. Freyrie A, Gallitto E, Gargiulo M, Mascoli C, Faggioli G, Pini R, et al.
Proximal aortic neck angle does not affect early and late EVAR out-
comes: an AnacondaTM Italian Registry analysis. J Cardiovasc Surg
(Torino) 2014;55:671-7.
22. Cochennec F, Becquemin JP, Desgranges P, Allaire E, Kobeiter H,
Roudot-Thoraval F. Limb graft occlusion following EVAR: clinical
pattern, outcomes and predictive factors of occurrence. Eur J Vasc
Endovasc Surg 2007;34:59-65.23. Maleux G, Koolen M, Heye S, Nevelsteen A. Limb occlusion after
endovascular repair of abdominal aortic aneurysms with supported
endografts. J Vasc Interv Radiol 2008;19:1409-12.
24. Oshin OA, Fisher RK, Williams LA, Brennan JA, Gilling-Smith GL,
Vallabhaneni SR, et al. Adjunctive iliac stents reduce the risk of stent-
graft limb occlusion following endovascular aneurysm repair with the
Zenith stent-graft. J Endovasc Ther 2010;17:108-14.
25. Bianchini Massoni C, Gargiulo M, Giovanetti F, Freyrie A, Faggioli GL,
Gallitto E, et al. Adjunctive stenting of endograft limbs during endo-
vascular treatment of infrarenal aortic and iliac aneurysms according to
3-projection completion angiography. J Endovasc Ther 2011;18:585-90.
26. Nordon IM, Karthikesalingam A, Hinchliffe RJ, Holt PJ, Loftus IM,
Thompson MM. Secondary interventions following endovascular
aneurysm repair (EVAR) and the enduring value of graft surveillance.
Eur J Vasc Endovasc Surg 2010;39:547-54.
27. Bendermacher BL, Stokmans R, Cuypers PW, Teijink JA, Van
Sambeek MR. EVAR reintervention management strategies in
contemporary practice. J Cardiovasc Surg (Torino) 2012;53:411-8.
28. Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Gouefﬁc Y,
Lermusiaux P, et al. A randomized controlled trial of endovascular
aneurysm repair versus open surgery for abdominal aortic aneurysms in
low- to moderate-risk patients. J Vasc Surg 2011;53:1167-73.
29. De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven EL,
Cuypers PW, et al. Long-term outcome of open or endovascular repair
of abdominal aortic aneurysm. N Engl J Med 2010;362:1881-9.
Submitted Mar 12, 2014; accepted Apr 29, 2014.
